Ambani Orgochem Reports 55% H1 FY27 Revenue Growth

Ambani Orgochem Limited reported H1 FY27 total income of ₹171.22 crore, a 54.87% year-on-year increase from ₹110.56 crore, supported by product approvals, Dahej contributions and growth in its customer base. The result matters because the company is pursuing capacity additions while managing lower operating margins, logistics constraints and working-capital requirements.

What did Ambani Orgochem report for H1 FY27?

Ambani Orgochem reported net sales turnover of ₹169.98 crore for the half year ended September 2026, compared with ₹109.15 crore in the corresponding prior-year period. Including other income of ₹1.24 crore, total income stood at ₹171.22 crore, versus ₹110.56 crore a year earlier.

The company said growth came from product approvals, Dahej beginning to contribute, an expanded customer base and additional customers. Management also said its solar, rubber and fragrance segments were generating revenue. The investor presentation and earnings-call materials described this as a strong first half, while management said it expected the second half to be better than the first half.

Profitability improved in absolute terms but trailed revenue growth. EBITDA was reported at ₹11.26 crore in the half-year results table, compared with ₹7.86 crore a year earlier. Other company materials cited EBITDA of ₹11.32 crore. Both sets of figures indicate growth of about 43% year on year and an EBITDA margin of roughly 6.6%, against approximately 7.2% in H1 FY26.

How did Ambani Orgochem's profit and margins change?

Ambani Orgochem's reported profit figures vary across the supplied disclosures, so investors should distinguish between the different presentations. The half-year results table shows profit and loss for the year of ₹2.73 crore for September 2026, compared with ₹0.20 crore in September 2025. Separately, the investor presentation and call-related materials cited net profit of about ₹3.45 crore to ₹3.50 crore, while another update cited ₹3.41 crore.

The difference is material because the reported net-profit growth rate depends on which figure is used. One update also stated that standalone profit was supported by an extraordinary item of ₹67.87 lakh. The supplied information does not provide a reconciliation between the ₹2.73 crore figure in the half-year table and the higher figures cited in the presentation-related summaries.

Operating profit rose to ₹10.02 crore from ₹6.45 crore, while depreciation increased to ₹2.11 crore from ₹1.86 crore. Interest expense was ₹5.28 crore, compared with ₹4.55 crore a year earlier. These items help explain why the rise in operating scale did not translate proportionately into the final profit measure.

Why is Dahej operating below capacity?

Ambani Orgochem said Dahej's peroxide capacity was operating at about 40% utilisation because transporting Class 5.2 materials through the region has been difficult. Management identified geopolitical conditions and logistics around the Strait of Hormuz as the main challenge, particularly for shipments to GCC markets.

The company said an easing of the Strait of Hormuz situation could unlock demand from the GCC. However, no timeline for a normalisation of logistics was provided. The utilisation constraint is significant because management identified Dahej as a contributor to first-half growth, but its peroxide operations are not yet running near full capacity.

The call materials also highlighted cash conversion, inventory, receivables and working-capital control as areas of focus. This is relevant as the company plans capital expenditure while managing a higher scale of operations. Management did not provide quantified guidance for revenue, margins or cash generation for the second half.

What capacity expansions is Ambani Orgochem planning?

Ambani Orgochem said Tarapur was fully utilised or operating above capacity and that it was expanding acrylic coatings capacity to meet demand from existing customers. The planned acrylic capacity addition is expected to increase capacity from about 2,000 tonnes per month to about 4,500 tonnes per month.

Management expects the Tarapur acrylic expansion to be completed by the end of Q4 FY27, with benefits visible from FY28. The investment is estimated at ₹15 crore to ₹20 crore, is already underway and is being funded through debt. The expansion is intended to address supply constraints rather than an announced new customer contract.

At Dahej, the company plans to expand salicylic acid capacity from about 50 tonnes per month to about 200 tonnes per month. Management expects this project to be completed in FY28 and said it would be funded substantially through a planned qualified institutional placement and warrant issue. Ambani Orgochem held an extraordinary general meeting on October 26, 2026, to consider changes to its authorised share capital and governing documents.

How do the results affect investors and operations?

The first-half figures show that Ambani Orgochem has increased revenue sharply, but margin performance remains an important monitorable. EBITDA grew more slowly than revenue, resulting in a lower reported EBITDA margin. Interest expense also increased year on year as the company prepares debt-funded expansion at Tarapur.

For operations, Tarapur capacity utilisation and Dahej logistics are the immediate factors affecting the company’s ability to serve demand. The company has stated that it cannot fully supply existing acrylic customers from current Tarapur capacity, while Dahej's peroxide operations remain restricted by shipping conditions. These are execution issues rather than confirmed earnings forecasts.

For shareholders, the planned QIP and warrant issue are relevant because management has identified them as a key source of funding for the Dahej project. The supplied materials do not state the size, timing or terms of the proposed capital raising. Investors will also need clarity on the differences between the profit figures reported in the half-year table and those cited in presentation-related updates.

Conclusion

Ambani Orgochem delivered 54.87% growth in H1 FY27 total income to ₹171.22 crore, with EBITDA rising by about 43%. The performance reflects product approvals, customer additions and initial Dahej contributions, but the lower EBITDA margin, higher interest expense and differing reported profit figures require careful reading of the disclosures.

The next disclosed milestones are completion of the Tarapur acrylic expansion by the end of Q4 FY27 and the expected FY28 completion of the Dahej salicylic acid project. Investors will also watch whether Class 5.2 shipping conditions improve, whether Dahej utilisation rises from about 40%, and how the company funds its planned expansion.